

September 2, 2015

# Relmada Therapeutics to Participate in Two Upcoming Investor Conferences

**Management Will Be Hosting Investor Meetings on September 9th in Boston, MA and September 10th in New York, NY**

NEW YORK, Sept. 2, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company's management will be hosting investor meetings at both the FBR Second Annual Healthcare Conference and BioCentury NewsMakers Conference. Details of the events are as follows:

## **FBR Second Annual Healthcare Conference**

Date: Wednesday, September 9

Location: Four Seasons, Boston

No presentation, investor meetings only

## **BioCentury NewsMakers Conference**

Date: Thursday, September 10

Location: Millennium Broadway Hotel, New York

No presentation, investor meetings only

Members of the investment community who are interested in meeting with Relmada's management team during the conference events should contact Christine Silverstein, director of investor relations at Relmada Therapeutics, at (212) 376-5779 or [csilverstein@relmada.com](mailto:csilverstein@relmada.com).

## **About Relmada Therapeutics, Inc.**

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: [www.relmada.com](http://www.relmada.com).

## **Forward-Looking Statements**

This news release contains "forward-looking statements." These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

## **Contact**

### **Investor Contact:**

Michael Becker, SVP of Finance and Corporate Development  
Relmada Therapeutics, Inc.  
Tel: 212-376-5776  
[mbecker@relmada.com](mailto:mbecker@relmada.com)

### **Media Contact:**

David Salisbury  
Berry & Company Public Relations  
Tel: 212-253-8881  
[dsalisbury@berrypr.com](mailto:dsalisbury@berrypr.com)

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-two-upcoming-investor-conferences-300136547.html>

SOURCE Relmada Therapeutics, Inc.